Search results for "Metformin"

showing 10 items of 126 documents

Does metformin induce ovulation in normoandrogenic anovulatory women?

2004

Objective: This study was undertaken to evaluate the efficacy of metformin in women with anovulation who do not have evidence for hyperandrogenism and classic polycystic ovary syndrome. Study design: A randomized trial of metformin (1500 mg daily) and placebo in 24 anovulatory women was undertaken for 3 months. Assessments of changes in hormone levels and insulin sensitivity were carried out. Abnormal ormonal values were defined by levels exceeding the range in normal ovulatory controls. Results: Anovulatory women had normal androgen levels and luteinizing hormone but had higher serum insulin and lower insulin sensitivity compared with controls. Over 3 months, there were 16 ovulatory cycles…

AdultOvulationmedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentDrug Administration ScheduleAnovulationInternal medicinemedicineHumansHypoglycemic AgentsInsulinOvulationMenstrual CycleMenstrual cyclemedia_commonbusiness.industryInsulinHyperandrogenismObstetrics and Gynecologymedicine.diseasePolycystic ovaryMetforminMetforminTreatment OutcomeEndocrinologyInfertilityFemaleHyperandrogenismLuteinizing hormonebusinessAnovulationPolycystic Ovary Syndromemedicine.drugAmerican Journal of Obstetrics and Gynecology
researchProduct

PCOS: metabolic impact and long-term management.

2012

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in women, affecting up to 10% of those in reproductive age. Furthermore, PCOS presents a lifetime risk of type II diabetes, cardiovascular diseases and endometrial cancer. Women with PCOS have increased cardiovascular risk; however, the risk is not the same in all patients and it is necessary to assess an individual risk profile. There is a discrepancy between increased cardiovascular risk at young age and postmenopausal number of cardiovascular events, probablu depending on changes in androgen ovarian function after the forties. However, changes with age of metabolic profile in women with PCOS have not been studied yet an…

AdultSettore MED/09 - Medicina InternaAdolescentComorbiditySettore MED/11 - Malattie Dell'Apparato CardiovascolareMetforminSettore MED/13 - EndocrinologiaDiabetes Mellitus Type 2Cardiovascular DiseasesRisk FactorsObesity AbdominalPCOS Metabolic Syndrome Cardiovascular risk aging insulin resistance hyperandrogenismHypertensionHumansFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceChildAntihypertensive AgentsDyslipidemiasPolycystic Ovary SyndromeMinerva ginecologica
researchProduct

Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Tr…

2005

Abstract Context: Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients. Objective: The goal of this study was to compare the effectiveness of metformin and CC administration as a first-line treatment in anovulatory women with PCOS. Design: We describe a prospective parallel randomized, double-blind, double-dummy controlled clinical trial. Setting: The study was conducted at the University “Magna Graecia” of Catanzaro, Catanzaro, Italy. Patients: One hundred nonobese primary infertile anovulatory women with PC…

Adultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryWEIGHT-LOSSIMPROVEMENTContext (language use)PLACEBO-CONTROLLED TRIALPlaceboTHERAPYBiochemistrylaw.inventionAnovulationEndocrinologyDouble-Blind MethodOvulation InductionRandomized controlled trialClomifenelawinsulin resistanceInternal medicinePCOSmedicineHumansCRITERIAclomipheneProspective StudiesPolycystic ovary syndromeGynecologybusiness.industryBiochemistry (medical)medicine.diseasePolycystic ovarymetformineMetforminPREGNANCYEndocrinologyPCOS; metformine; clomipheneovulationFemaleOvulation inductionGLUCOSE-TOLERANCEclomifenemetforminbusinessOBESE WOMENAnovulationmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients

2015

Abstract Objective We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects. Methods The study population consisted of 40 reproductive-age women with PCOS, who underwent treatment with metformin during a 12-week period, and their corresponding matched controls (n = 44). We evaluated endocrinological parameters, adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)) in serum. In addition, interactions between human umbili…

Adultmedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndotheliumType 2 diabetesProinflammatory cytokineYoung AdultInsulin resistanceInternal medicineCell AdhesionHuman Umbilical Vein Endothelial CellsLeukocytesmedicineHumansLeukocyte RollingEndothelium Leukocyte Metformin Mitochondria PCOS Type 2 diabetesCells CulturedCell adhesion moleculebusiness.industryEndothelial Cellsnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryCoculture TechniquesMetforminMetforminEndothelial stem cellTreatment Outcomemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2SpainCytokinesFemaleInflammation MediatorsCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersPolycystic Ovary Syndromemedicine.drugAtherosclerosis
researchProduct

Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.

2015

ObjectiveOxidative stress and mitochondrial dysfunction are implicated in polycystic ovary syndrome (PCOS). The present study assesses the effect of metformin treatment on mitochondrial function in polymorphonuclear cells from PCOS subjects. Additionally, we evaluate endocrine parameters and levels of interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα).Design and methodsOur study population was comprised of 35 women of reproductive age diagnosed with PCOS and treated with metformin for 12 weeks, and their corresponding controls (n=41), adjusted by age and BMI. We evaluated the alteration of endocrinological and anthropometrical parameters and androgen levels. Mitochondrial O2 consum…

Adultmedicine.medical_specialtyendocrine system diseasesNeutrophilsEndocrinology Diabetes and MetabolismMitochondrionBiologymedicine.disease_causechemistry.chemical_compoundYoung AdultEndocrinologyDehydroepiandrosterone sulfateInsulin resistanceInternal medicinemedicineHumansHypoglycemic Agentschemistry.chemical_classificationReactive oxygen speciesInterleukin-6Tumor Necrosis Factor-alphanutritional and metabolic diseasesGeneral MedicineGlutathionemedicine.diseasePolycystic ovaryMetforminMetforminMitochondriaEndocrinologyTreatment OutcomechemistryFemaleInsulin ResistanceOxidative stressmedicine.drugPolycystic Ovary Syndrome
researchProduct

Uterine effects of metformin administration in anovulatory women with polycystic ovary sindrome

2006

Background Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whil…

Adultmedicine.medical_specialtyendocrine system diseasesPhysiologymedia_common.quotation_subjectUterusEndometriumFertility AgentsAnovulationEndometriumanovulation; endometrium; metforminMenstruation-Inducing AgentUltrasoundmedicinePCOSHumansOvulationFertility Agentmedia_commonGynecologyMenstruation-Inducing Agentsbusiness.industryRehabilitationUterusanovulation endometrium metformin PCOS ultrasoundnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMetforminMetforminPregnancy ratemedicine.anatomical_structureUteruReproductive MedicineIn uteroRegional Blood FlowFemalebusinessmedicine.drugAnovulationHumanPolycystic Ovary SyndromeDevelopmental Biology
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutra…

2021

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between KRas and GSK-3. To further elucidate the roles of GSK-3β in drug-resistance, we transfected KRas-dependent MIA-PaCa-2 pancreatic cells with wild-type (WT) and kinase-dead (KD) forms of GSK-3β. Transfection of MIA-PaCa-2 cells with WT-GSK-3β increased their resistance to various chemotherapeutic drugs and certain small molecule inhibitors. Transfection of cells with KD-GSK-3β often increased therapeutic sensitivity. An exception was observed wi…

Berberineendocrine system diseasesmedicine.medical_treatmentRegulatormedicine.disease_causeDeoxycytidinePiperazinesTargeted therapychemotherapeutic drugsTargeted therapyNitrophenolsBreast cancerGSK-3BGlycolysisMolecular Targeted TherapyNeoplasm Metastasistargeted therapy;lcsh:QH301-705.5Tumor Stem Cell AssaySulfonamidesTumorbiologyChemistryGeneral MedicineTransfectionMetforminDisease ProgressionMCF-7 CellsFemaleKRASNutraceuticalsFluorouracilSignal transductionGlycolysisSignal TransductionBCL2bcl-X ProteinAntineoplastic AgentsBreast Neoplasmsmacromolecular substancesAdenocarcinomaArticleCell LineInhibitory Concentration 50Cell Line TumorThiadiazolesmedicineDiabetes MellitusKRasHumansGlycogen synthaseProtein Kinase InhibitorsCell ProliferationChemotherapeu-tic drugsGlycogen Synthase Kinase 3 betaGSK-3βAdenylate KinaseBiphenyl Compoundsnutraceuticals;PDACβ-cateninGemcitabine?-cateninMalariaPancreatic Neoplasmslcsh:Biology (General)MCF-7DoxorubicinDietary SupplementsCancer researchbiology.protein
researchProduct

Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes

2020

Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However, many patients with T2D do not respond to or tolerate metformin well. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin. We explored whether blood-based epigenetic markers could discriminate metformin response and tolerance by analyzing genome-wide DNA methylation in drug-naïve patients with T2D at the time of their diagnosis. DNA methylation of 11 and 4 sites differed between glycemic responders/nonresponders and metformin-tolerant/intolerant patients, respectively, in discovery and replication cohorts. Greater methylation at these sites associ…

Blood Glucose0301 basic medicineOncologymedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismType 2 diabetesEpigenesis Genetic03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEpigeneticsGlycemicbusiness.industrynutritional and metabolic diseasesGeneral MedicineOdds ratioDNA Methylationmedicine.diseaseMetformin3. Good healthMetforminDrug-naïve030104 developmental biologyDiabetes Mellitus Type 2Pharmaceutical PreparationsDNA methylationbusinessmedicine.drugScience Translational Medicine
researchProduct